---
title: "OrbiMed Advisors disposes of 115,844 Sionna Therapeutics shares worth $5.27 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291587694.md"
description: "OrbiMed Advisors sold 115,844 shares of Sionna Therapeutics on June 30, 2026, at $45.5 per share, totaling approximately $5.27 million. Following this transaction, OrbiMed's indirect stake decreased to 2,555,877 shares."
datetime: "2026-07-02T20:43:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291587694.md)
  - [en](https://longbridge.com/en/news/291587694.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291587694.md)
---

# OrbiMed Advisors disposes of 115,844 Sionna Therapeutics shares worth $5.27 million

-   OrbiMed Advisors reported selling 115,844 Sionna Therapeutics common shares on June 30, 2026 at USD 45.5. \* Stake fell to 2,555,877 shares held indirectly following the sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000683), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SION.US](https://longbridge.com/en/quote/SION.US.md)

## Related News & Research

- [Sionna Therapeutics (SION) Pulls Back On CF Hopes With Valuation Still In Focus](https://longbridge.com/en/news/293289887.md)
- [Sionna Therapeutics Chief Legal Officer Jennifer Fitzpatrick disposes of 10,250 common shares worth $446,862.08](https://longbridge.com/en/news/291975794.md)
- [Bicara Therapeutics director Christy J. Oliger files initial beneficial ownership statement](https://longbridge.com/en/news/294255131.md)
- [Rapport Therapeutics CEO Abraham Ceesay sells 2,210 shares worth $92,999.37](https://longbridge.com/en/news/294252845.md)
- [Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statement](https://longbridge.com/en/news/293969051.md)